These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33153130)

  • 1. Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Payne K; Pugh M; Brooks J; Batis N; Taylor G; Nankivell P; Mehanna H
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Cell Molecular Profiling of Head and Neck Squamous Cell Carcinoma Reveals Five Dysregulated Signaling Pathways Associated With Circulating Tumor Cells.
    Stucky A; Viet CT; Aouizerat BE; Ye Y; Doan C; Mundluru T; Sedhiazadeh P; Sinha UK; Chen X; Zhang X; Li SC; Cai J; Zhong JF
    Cancer Control; 2024; 31():10732748241251571. PubMed ID: 38869038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune gene expression in head and neck squamous cell carcinoma patients.
    Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
    Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
    Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
    Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma.
    Tada H; Takahashi H; Kawabata-Iwakawa R; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Chikamatsu K
    Sci Rep; 2020 Dec; 10(1):21573. PubMed ID: 33299117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
    Chikamatsu K; Tada H; Takahashi H; Kuwabara-Yokobori Y; Ishii H; Ida S; Shino M
    Oral Oncol; 2019 Feb; 89():34-39. PubMed ID: 30732956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour cells predict recurrences and survival in head and neck squamous cell carcinoma patients.
    Zhang X; Weeramange CE; Hughes BGM; Vasani S; Liu ZY; Warkiani M; Hartel G; Ladwa R; Thiery JP; Kenny L; Breik O; Punyadeera C
    Cell Mol Life Sci; 2024 May; 81(1):233. PubMed ID: 38780775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
    Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
    BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour cell PD-L1 test for head and neck cancers.
    Kulasinghe A; Kenny L; Punyadeera C
    Oral Oncol; 2017 Dec; 75():6-7. PubMed ID: 29224824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma.
    Hsieh JC; Lin HC; Huang CY; Hsu HL; Wu TM; Lee CL; Chen MC; Wang HM; Tseng CP
    Head Neck; 2015 Oct; 37(10):1448-55. PubMed ID: 24844673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
    Baysal H; Siozopoulou V; Zaryouh H; Hermans C; Lau HW; Lambrechts H; Fransen E; De Pauw I; Jacobs J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; De Waele J; Wouters A
    Front Immunol; 2022; 13():1001161. PubMed ID: 36268020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
    Zhu W; Ye Z; Chen L; Liang H; Cai Q
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
    Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
    Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
    Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
    Histopathology; 2024 Jul; 85(1):133-142. PubMed ID: 38606992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A Review.
    Aktar S; Baghaie H; Islam F; Gopalan V; Lam AK
    Otolaryngol Head Neck Surg; 2023 May; 168(5):988-1005. PubMed ID: 36939466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immunogenic cell death-related damage-related molecular patterns (DAMPs) to predict outcomes in patients with head and neck squamous cell carcinoma.
    Zhang J; Shi X; Wang M; Zhai R; Wang M; Gong Z; Ni Z; Xu T; Zhu W; Liu L
    J Cancer Res Clin Oncol; 2024 May; 150(5):240. PubMed ID: 38713284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.